R&D Insight

2022 GLASS report / JPIAMR survey on 2025-2032 funding plan

Dear All, First up for today, WHO’s GLASS (Global Antimicrobial Resistance and Use Surveillance System) have released an update to their ongoing work that provides global data through 2020. Here the links you need: The GLASS dashboard The GLASS report An insightful LinkedIn post on the way(s) that the data can now be used: you

Read More »

WHO releases its Fungal Priority Pathogen List (PPL)!

Dear All, Based on a 2020 RFP, we’ve known that WHO was building a fungal priority pathogen list (PPL). Well, now the list has been released. Here’s what you need to understand the new PPL: Webpage where you can get the report My PowerPoint .pptx that summarizes all the PPLs to date My webpage that provides

Read More »

WHO 2017 Priority Pathogens List

Dear All: The new WHO priority pathogen list for R&D has been released! It’s entirely focused on bacteria both otherwise has a lot of similarity the CDC list. FYI, CARB-X will use both lists going forward. Links to WHO materials are below. I have also prepared a short slide deck (updated on 22 Dec 2017) that shows

Read More »

CDC-FDA webinar: Developing drugs to prevent healthcare-associated infections (30 Aug 2022)

Dear All, A quick note today to call your attention to an upcoming webinar that will be of wide interest. Substantial new details have been added to the online agenda materials for the 30 August 2022 (virtual, 8.30a-5.00p ET) webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very

Read More »

IDWeek 2022: New pipeline sessions seek presentation of therapeutics and diagnostics!

Dear All: I have learned that the program for IDWeek 2022 will have specific dedicated pipeline sessions for therapeutics and diagnostics. The online details are relatively scant, but my understanding is that the therapeutics of interest for these sessions include antibacterials, antifungals, and non-HIV, non-COVID antiviral agents. There do not appear to be any constraints

Read More »

Outstanding discussions of Pull, the NHS Pilot, and Antibiotic value

Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:

Read More »

Implementing your National Action Plan: Tell your story!

Dear All, Building on the success of the previous Call to Action on Antimicrobial Resistance (AMR) conferences held in Berlin (2017) and Ghana (2018), the governments of Denmark, Colombia, Ghana and Zambia, with the International Centre for AMR Solutions (ICARS), UN Foundation, UNICEF, and the Wellcome Trust, are together organizing a follow-up Call to Action

Read More »

Beyond Pull: Maximizing availability + (appropriate!) use / Help needed!

Dear All, Today we have two interwoven topics to consider: An analysis of research priorities (not all technical!) and a triad of related initiatives, each of which comes with an opportunity for you to starting working on some of those priorities! First up, we have an excellent new paper summarizing the perspective of 32 experts

Read More »
Scroll to Top